Daxor Corporation (NASDAQ:DXR – Get Free Report) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 2,083 shares, a decrease of 66.2% from the May 31st total of 6,164 shares. Based on an average daily volume of 2,060 shares, the short-interest ratio is presently 1.0 days. Currently, 0.1% of the company’s stock are sold short.
Daxor Stock Down 2.9%
Shares of DXR stock traded down $0.30 during trading hours on Friday, hitting $10.02. The company’s stock had a trading volume of 1,854 shares, compared to its average volume of 2,168. The company has a 50 day moving average of $10.34 and a 200 day moving average of $11.48. Daxor has a 12-month low of $8.56 and a 12-month high of $14.76.
Daxor (NASDAQ:DXR – Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported ($0.10) earnings per share (EPS) for the quarter.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on DXR
Hedge Funds Weigh In On Daxor
Institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. purchased a new stake in shares of Daxor in the second quarter worth about $86,000. Crescent Grove Advisors LLC purchased a new position in Daxor during the first quarter valued at approximately $104,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Daxor during the fourth quarter valued at approximately $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Daxor in the first quarter valued at approximately $245,000. Finally, Aristides Capital LLC acquired a new position in Daxor in the first quarter valued at approximately $403,000. Hedge funds and other institutional investors own 1.34% of the company’s stock.
About Daxor
Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.
Featured Articles
- Five stocks we like better than Daxor
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
